NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Forecast, Price & News

$6.55

+0.50 (+8.26%)

(As of 05:22 PM ET)

Compare

Today's Range: $6.03
▼
$6.68
50-Day Range: $3.22
▼
$7.27
52-Week Range: $2.19
▼
$7.45

Volume: 201,206 shs
Average Volume: 177,470 shs
Market Capitalization: $266.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.25

Olema Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 132.8% Upside
$15.25 Price Target
Short Interest: Bearish
2.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$30,200 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.79) to ($2.92) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

450th out of 981 stocks

Pharmaceutical Preparations Industry

212th out of 476 stocks

3.5

Analyst's Opinion

Consensus Rating
Olema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.25, Olema Pharmaceuticals has a forecasted upside of 132.8% from its current price of $6.55.
Amount of Analyst Coverage
Olema Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.97% of the float of Olema Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Olema Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Olema Pharmaceuticals has recently increased by 0.98%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Olema Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Olema Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OLMA.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Olema Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
MarketBeat Follows
2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,200.00 in company stock.
Percentage Held by Insiders
23.50% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.41% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.79) to ($2.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Olema Pharmaceuticals is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Olema Pharmaceuticals is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Olema Pharmaceuticals has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OLMA Stock News Headlines

May 30, 2023 | finance.yahoo.com

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

May 19, 2023 | finance.yahoo.com

Institutional investors own a significant stake of 42% in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

June 8, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

May 16, 2023 | americanbankingnews.com

Q3 2023 Earnings Estimate for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Issued By Capital One Financial

May 13, 2023 | americanbankingnews.com

Capital One Financial Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $20.00

May 11, 2023 | msn.com

HC Wainwright & Co. Maintains Olema Pharmaceuticals (OLMA) Buy Recommendation

May 11, 2023 | finance.yahoo.com

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

May 10, 2023 | americanbankingnews.com

HC Wainwright Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $14.00

June 8, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

May 9, 2023 | finance.yahoo.com

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023 | finance.yahoo.com

Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress

May 6, 2023 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Capital One Financial

May 5, 2023 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated at Capital One Financial

May 2, 2023 | americanbankingnews.com

Lifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:OLMA)

April 29, 2023 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Receives "Outperform" Rating from Lifesci Capital

April 29, 2023 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Rating Reiterated by Lifesci Capital

April 29, 2023 | americanbankingnews.com

Lifesci Capital Reiterates "Outperform" Rating for Olema Pharmaceuticals (NASDAQ:OLMA)

April 13, 2023 | finance.yahoo.com

Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

March 11, 2023 | marketwatch.com

Olema Pharmaceuticals to Reduce Workforce by 25% Amid Broader Restructuring

March 11, 2023 | seekingalpha.com

Olema Pharmaceuticals GAAP EPS of -$0.65 in-line

March 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), COMPASS Pathways (CMPS) and Olema Pharmaceuticals (OLMA)

March 9, 2023 | seekingalpha.com

OLMA

March 9, 2023 | finance.yahoo.com

Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update

March 2, 2023 | benzinga.com

Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference

February 21, 2023 | finance.yahoo.com

Olema Oncology to Participate at Upcoming Investor Conferences

January 2, 2023 | finance.yahoo.com

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully

December 7, 2022 | finance.yahoo.com

Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

See More Headlines

OLMA Price History

30 days | 90 days | 365 days | Advanced Chart

OLMA Company Calendar

Last Earnings: 5/09/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OLMA
CUSIP: N/A
CIK: 1750284
Web: www.olema.com
Phone: 650-243-5555
Fax: N/A
Employees: 73
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.25
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +132.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.26%
Return on Assets: -49.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.76
Quick Ratio: 9.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.90 per share
Price / Book: 1.34

Miscellaneous

Outstanding Shares: 40,760,000
Free Float: 31,183,000
Market Cap: $266.98 million
Optionable: Not Optionable
Beta: 2.32

Key Executives

Dr. Sean P. Bohen M.D. (Age 56)
Ph.D., Pres, CEO & Director
Comp: $999.3k

Mr. Shane William Charles Kovacs M.B.A. (Age 49)
Chief Operating & Financial Officer
Comp: $875.55k

Dr. Cyrus L. Harmon Ph.D. (Age 52)
Chief Research Officer & Director

Mr. Kinney Horn (Age 49)
Chief Bus. Officer
Comp: $588.3k

Dr. Peter J. Kushner Ph.D. (Age 84)
Co-Founder & Sr. Research Fellow

Ms. Courtney Dugan
VP of Investor Relations & Communications

Mr. John B. Moriarty Jr. (Age 55)
Exec. VP, Chief Legal Officer & Corp. Sec.

Ms. Julie Dexter
VP & Head of People

Dr. David C. Myles Ph.D. (Age 60)
Chief Discovery & Non-Clinical Devel. Officer

Ms. Demiana Faltaos Ph.D.
Pharm.D., VP & Head of Clinical Pharmacology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OLMA Stock - Frequently Asked Questions

Should I buy or sell Olema Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OLMA shares.
View OLMA analyst ratings or view top-rated stocks.
What is Olema Pharmaceuticals' stock price forecast for 2023?: 5 analysts have issued 12 month price targets for Olema Pharmaceuticals' stock. Their OLMA share price forecasts range from $11.00 to $20.00. On average, they predict the company's stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 132.8% from the stock's current price.
View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts.
How have OLMA shares performed in 2023?: Olema Pharmaceuticals' stock was trading at $2.45 at the beginning of 2023. Since then, OLMA shares have increased by 167.3% and is now trading at $6.55.
View the best growth stocks for 2023 here.
When is Olema Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our OLMA earnings forecast.
How were Olema Pharmaceuticals' earnings last quarter?: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.04.
When did Olema Pharmaceuticals IPO?: (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO.

What is Olema Pharmaceuticals' stock symbol?: Olema Pharmaceuticals trades on the NASDAQ under the ticker symbol "OLMA."
Who are Olema Pharmaceuticals' major shareholders?: Olema Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.45%), Sectoral Asset Management Inc. (2.45%), Geode Capital Management LLC (0.86%), Vontobel Holding Ltd. (0.83%), Renaissance Technologies LLC (0.63%) and Deutsche Bank AG (0.63%). Insiders that own company stock include Bvf Partners L P/Il, Cormorant Asset Management, Lp, Cyrus Harmon, G Walmsley Graham, Kinney Horn and Sean Bohen.
View institutional ownership trends.
How do I buy shares of Olema Pharmaceuticals?: Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Olema Pharmaceuticals' stock price today?: One share of OLMA stock can currently be purchased for approximately $6.55.
How much money does Olema Pharmaceuticals make?: Olema Pharmaceuticals (NASDAQ:OLMA) has a market capitalization of $266.98 million. The company earns $-104,790,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.
How can I contact Olema Pharmaceuticals?: Olema Pharmaceuticals' mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The official website for the company is www.olema.com. The company can be reached via phone at 650-243-5555 or via email at ir@olema.com.

This page (NASDAQ:OLMA) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Olema Pharmaceuticals (OLMA) Stock Forecast, Price & News

Olema Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Olema Pharmaceuticals (NASDAQ:OLMA) Stock

OLMA Stock News Headlines

OLMA Price History

OLMA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OLMA Stock - Frequently Asked Questions

Overall MarketRank^™